leisure time -WSS

leisure time

author：explore 2025-09-30 20:06:14 - browse：2

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： The biotech scorecard for Q3: 15 stock

focus

WSS

What affirmative action's end means to a medical student

RaDonda Vaught case: a double standard for nurses, physicians

Skip the lead apron during X

4th of July breaks record for highest global temperature ever measured

Being 'nonadherent' patient made me a more empathetic doctor

How Robert F. Kennedy Jr. distorted vaccine science

hotspot

leisure time

entertainment

Walensky prepares to leave CDC — and Congress — behind

Doctor appointment wait times are getting worse

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Community addresses injustice for Long Island mothers

Continuity nursing helped my family in our darkest PICU moments

'Screen and refer' systems are hurting patients

Medical leaders decry Supreme Court decision on affirmative action

Doctor appointment wait times are getting worse

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Beware reading your test results before your doctor does

leisure time

Option Care buys Amedisys in $3.6 billion home care deal

Connecting traumatic brain injury and domestic violence

Pfizer's Covid pill remains 89% effective in final analysis, company says

Being 'nonadherent' patient made me a more empathetic doctor

Prescription digital therapeutics are key to pharma’s future

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

focus

leisure time

focus

focus